[1]
Roselli M, Finamore A. Use of synbiotics for ulcerative colitis treatment. Curr Clin Pharmacol 2020; 15(3): 174-82.
[http://dx.doi.org/10.2174/1574884715666191226120322]
[http://dx.doi.org/10.2174/1574884715666191226120322]
[2]
Jayanama K, Theou O. Effects of probiotics and prebiotics on frailty and ageing: A narrative review. Curr Clin Pharmacol 2020; 15(3): 183-92.
[http://dx.doi.org/10.2174/1574884714666191120124548]
[http://dx.doi.org/10.2174/1574884714666191120124548]
[3]
Brognara L, Salmaso L, Mazzotti A, Di Martino A, Faldini C, Cauli O. Effects of probiotics in the management of infected chronic wounds: From cell culture to human studies. Curr Clin Pharmacol 2020; 15(3): 193-206.
[http://dx.doi.org/10.2174/1574884714666191111130630]
[http://dx.doi.org/10.2174/1574884714666191111130630]
[4]
Naseer M, Poola S, Uraz S, Tahan V. Therapeutic effects of prebiotics in constipation: A review. Curr Clin Pharmacol 2020; 15(3): 207-15.
[http://dx.doi.org/10.2174/1574884715666200212125035]
[http://dx.doi.org/10.2174/1574884715666200212125035]
[5]
Naseer M, Poola S, Ali S, Samiullah S, Tahan V. Prebiotics and probiotics in Inflammatory Bowel Disease (IBD): Where are we now and where are we going? Funders. Curr Clin Pharmacol 2020; 15(3): 216-33.
[http://dx.doi.org/10.2174/1574884715666200312100237]
[http://dx.doi.org/10.2174/1574884715666200312100237]
[6]
Vlachou E, Ntikoudi A, Govina O, et al. Effects of probiotics on diabetic nephropathy: A systematic review. Curr Clin Pharmacol 2020; 15(3): 234-42.
[http://dx.doi.org/10.2174/1574884715666200303112753]
[http://dx.doi.org/10.2174/1574884715666200303112753]
16
1